Xponance Inc. Acquires 2,141 Shares of DexCom, Inc. (NASDAQ:DXCM)

Xponance Inc. grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 89,460 shares of the medical device company’s stock after buying an additional 2,141 shares during the quarter. Xponance Inc.’s holdings in DexCom were worth $10,143,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Capital World Investors increased its holdings in DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Artisan Partners Limited Partnership raised its position in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares during the last quarter. Capital Research Global Investors lifted its stake in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after acquiring an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC boosted its position in DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after acquiring an additional 1,398,136 shares during the last quarter. Finally, Congress Asset Management Co. MA grew its stake in shares of DexCom by 2,076.3% during the 4th quarter. Congress Asset Management Co. MA now owns 1,126,382 shares of the medical device company’s stock worth $139,773,000 after acquiring an additional 1,074,626 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $69.70 on Tuesday. The firm has a market cap of $27.72 billion, a P/E ratio of 44.97, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The business’s 50 day moving average is $77.32 and its 200-day moving average is $108.93. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.34 earnings per share. Equities research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. Insiders have sold 2,483 shares of company stock valued at $201,708 over the last 90 days. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent research reports. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. UBS Group decreased their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Robert W. Baird upped their target price on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Wells Fargo & Company decreased their price target on DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Finally, JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $145.00 to $75.00 in a research note on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.